# SEG Drug HTML Blocker Resolution Report

**Document ID:** `SEG_DRUG_HTML_BLOCKER_RESOLUTION_REPORT`  
**Mode:** `CONTROLLED CONTENT GOVERNANCE EXECUTION`  
**Review pathway:** `OWNER_GOVERNED_MEDICAL_REVIEW_PATHWAY`  
**Source:** Drug HTML  
**Ownership:** `SEG_INTERNAL_ASSET` for the declared retained artifact scope  
**Current review decision:** `OWNER_REVIEW_BLOCKED`

## 1. Resolution boundary

This report resolves blockers only at the level of evidence inventory, field definition, and review preparation. It does not resolve clinical correctness, drug safety, rights, provenance, canonical source identity, version currency, or source approval. No drug content was corrected, rewritten, normalized, imported, or activated.

## 2. Locked artifact evidence

| Field | Observed value | Resolution state |
|---|---|---|
| Artifact ID | `LOCAL_INTAKE_ARTIFACT` | `CONFIRMED` for retained artifact identity |
| Artifact path | `/home/ubuntu/upload/deepseek_html_20260615_a3266b.html` | `CONFIRMED` |
| Size | 25,918 bytes | `CONFIRMED` |
| Line count | 394 lines | `CONFIRMED` |
| SHA-256 | `5367711d08df2393cf852815b1b9d0ad4dac8240ac061cd88c71a53884e938ac` | `CONFIRMED` |
| Canonical source/title | `NOT_AVAILABLE` | Blocking |
| Publisher/owner/custodian | `NOT_AVAILABLE` | Blocking |
| Edition/version/date | `NOT_AVAILABLE` | Blocking |
| Original URL/locator | `NOT_AVAILABLE` | Blocking |
| Extraction/transformation history | `NOT_AVAILABLE` | Blocking |
| Rights/display/redistribution scope | `NOT_AVAILABLE` | Blocking |

The artifact-level hash and structure establish retained-byte continuity only. They do not establish source authority, clinical correctness, currentness, or rights clearance.[1] [2]

## 3. Metadata inventory

The following metadata fields are required for controlled review and downstream governance. The current evidence is recorded without inference.

| Metadata field | Current status | Required closure evidence |
|---|---|---|
| SEG artifact/source ID | `CONFIRMED` as `LOCAL_INTAKE_ARTIFACT` | Preserve the locked ID and hash link |
| Canonical source title | `NOT_AVAILABLE` | Authoritative title from source owner/custodian or verifiable original locator |
| Publisher/owner/custodian | `NOT_AVAILABLE` | Attributable owner or custodian statement |
| Author/organization | `NOT_AVAILABLE` | Source-level author/organization evidence |
| Edition/version | `NOT_AVAILABLE` | Version, edition, release label, or governed equivalent |
| Publication/update date | `NOT_AVAILABLE` | Source-supplied or independently verifiable date |
| Original URL/locator | `NOT_AVAILABLE` | Stable original locator and access evidence |
| Language | Partially observed in artifact; canonical metadata not closed | Explicit governed metadata entry |
| Professional track | Not established by filename/topic alone | Explicit track/taxonomy decision |
| Taxonomy ID/version | `NOT_AVAILABLE` | Supplied taxonomy identifier and version |
| Provenance/extraction lineage | `NOT_AVAILABLE` | Origin, transformation, extraction, and chain-of-custody record |
| Rights/text-display scope | `NOT_AVAILABLE` | Rights/licence/permission evidence for retained and displayed material |
| Review state | `OWNER_REVIEW_BLOCKED` | Attributable source-specific review record |
| Audit linkage | Start and assessment events recorded; closure evidence absent | Append-only review finding and disposition events |

## 4. Structure and clinical-field inventory

Read-only structure observations record 19 `summaryData` sections, 21 `quick` entries, 47 `drugList` entities, and 20 `trapsList` entries. These observations are useful for review scope but are not a clinical validation.

The following clinical fields must be checked at entity and section level. The current evidence does not establish whether any field is complete, current, or safe; `NOT_ESTABLISHED` is therefore used instead of treating an unobserved field as absent.

| Clinical field group | Required checks | Current status |
|---|---|---|
| Drug identity | Generic/active ingredient, brand/alias, formulation, concentration, route, and entity disambiguation | `NOT_ESTABLISHED` |
| Indication and emergency relevance | Indication, emergency context, intended population, exclusions, and clinical scope | `NOT_ESTABLISHED` |
| Dose and administration | Dose, units, route, frequency, timing, maximums, adjustments, and administration instructions | `NOT_ESTABLISHED` |
| Contraindications and precautions | Contraindications, allergies, pregnancy/renal/hepatic cautions, age/weight limits, and high-risk warnings | `NOT_ESTABLISHED` |
| Interactions | Drug-drug, drug-disease, duplicate therapy, and interaction-source references | `NOT_ESTABLISHED`; no explicit pairwise interaction table was observed in the available evidence, which is not evidence of absence |
| Adverse effects and monitoring | Adverse effects, toxicity, monitoring, escalation, and follow-up requirements | `NOT_ESTABLISHED` |
| Safety and currency | Current guideline/protocol alignment, safety notices, version/date, and source citation | `NOT_ESTABLISHED` |
| Traceability | Entity-to-section locator, source locator, version, reviewer finding, and audit event | `INCOMPLETE` |

No clinical field was declared missing as a medical fact solely because it was not visible in the available evidence. The inventory identifies what the qualified review must establish.

## 5. Drug safety review checklist

A qualified owner-governed Pharmacology/Drug Safety review must complete each applicable check against the exact artifact and hash.

| Check | Required evidence or disposition |
|---|---|
| Entity identity | Confirm or flag ambiguity with exact section/entity locator |
| Formulation/concentration | Record the source wording and identify unresolved variants |
| Dose and units | Reconcile every dose, unit, route, frequency, and maximum against the authorized reference set |
| Contraindications/precautions | Record explicit content, omissions, ambiguity, and population limits without silently correcting the artifact |
| Interactions | Record the observed interaction representation, its limits, and whether a separate interaction reference is required |
| High-risk medication flags | Identify applicable high-risk items and document the safety disposition |
| Adverse effects/monitoring | Check whether clinically material adverse-effect and monitoring information is represented and traceable |
| Emergency-medicine applicability | Record scope and learner-level suitability separately from drug-safety validation |
| Currency/version | Tie the review to a source version/date or record the unresolved status |
| Source citations | Require exact source locators and preserve unresolved citation gaps |
| Ambiguity/truncation | Record any ambiguous, truncated, duplicated, or conflicting representation; do not repair in place |
| Final disposition | `TO_BE_COMPLETED_BY_AUTHORIZED_REVIEWER`; a preparation report cannot grant approval |

## 6. Required medical decisions

The following decisions are required from attributable owner-governed review records; none is supplied or created by this report:

| Decision area | Required decision |
|---|---|
| Emergency Medicine relevance | Determine whether each reviewed scope is appropriate, incomplete, ambiguous, or requires action, with locators |
| Drug information structure | Determine whether entity and section organization is sufficiently traceable for the declared educational use |
| Pharmacology/Drug Safety | Determine whether each applicable safety field is supported, unresolved, unsafe to use, or requires remediation |
| Metadata acceptance | Determine whether required metadata is complete or remains blocked |
| Rights/provenance disposition | Record a separate rights/provenance decision; internal ownership does not clear third-party material |
| Overall owner review outcome | `TO_BE_COMPLETED_BY_AUTHORIZED_REVIEWER`; cannot be inferred from this report |

## 7. Resolved blockers at this stage

The following blockers are resolved only as documentation or retained-artifact evidence:

1. The exact retained artifact, path, size, line count, and SHA-256 are locked.
2. The available structural inventory is recorded and bounded as non-clinical evidence.
3. The metadata fields and clinical/drug-safety review checklist are explicitly defined.
4. The required decision domains and non-actions are recorded.

These resolutions do not close the underlying identity, rights, provenance, clinical, safety, metadata, or approval gates.

## 8. Remaining blockers and evidence still required

The canonical source identity, publisher/custodian, version/date, original locator, extraction history, complete provenance, rights/display scope, professional-track/taxonomy evidence, and attributable dated Emergency Medicine and Pharmacology/Drug Safety review records remain open. Technical HTML/lineage review and append-only finding/disposition events also remain required.

The next allowed action is to assemble the evidence packet, preserve the HTML unchanged, and complete the separate owner-governed Emergency Medicine, Pharmacology/Drug Safety, metadata, technical, rights, provenance, and audit streams. No content record or normalized representation may be created from this report.

## 9. Controls

```text
APPROVED_SOURCES = NONE
NORMALIZATION = BLOCKED_PENDING_APPROVED_SOURCE
READY_FOR_NORMALIZATION = NOT_SET
SOURCE_REGISTRY_APPROVAL_STATES = UNCHANGED
```

## References

[1]: file:///home/ubuntu/seg-internship-output/SEG_DRUG_HTML_OWNER_REVIEW_RECORD.md "SEG Drug HTML Owner Review Record"

[2]: file:///home/ubuntu/seg-internship-output/SEG_P0_VERSION_CONTROL_REGISTER.md "SEG P0 Version Control Register"

[3]: file:///home/ubuntu/seg-internship-output/SEG_OWNER_REVIEW_AUTHORITY_POLICY.md "SEG Owner Review Authority Policy"

[4]: file:///home/ubuntu/seg-internship-output/SEG_OWNER_REVIEW_CLOSURE_ASSESSMENT_REPORT.md "SEG Owner Review Closure Assessment Report"

**Document status:** `DRUG_HTML_BLOCKER_RESOLUTION_DOCUMENTED_PENDING_EVIDENCE_AND_REVIEW`
